Previous studies have found evidence that MET receptor expression is significantly increased in ALK-positive NSCLC10 and that the tumour microenvironment is altered during TKI treatment, which may increase the production of HGF and contribute to resistance onset18. This evidence concerns the gene ALK and neoplasm.